Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics.
Antimicrob Agents Chemother
; 67(4): e0239721, 2023 04 18.
Article
em En
| MEDLINE
| ID: mdl-36916956
ABSTRACT
Omadacycline is approved in the United States for the treatment of patients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections. Analyses were undertaken to evaluate pharmacokinetic differences among subjects or patients stratified by comorbidities. Differences in clearance by smoking status, history of diabetes mellitus, chronic lung disease, hypertension, heart failure, or coronary artery disease were evaluated using a Welch two-sample t test. Smoking was the only significant comorbidity after correction for sex, with a clinically insignificant difference of 13%. Omadacycline dose adjustments based on these comorbidities do not appear to be warranted.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Infecções Comunitárias Adquiridas
/
Antibacterianos
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article